Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma-Reference-Cited by-同舟云学术

Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma

Published:2021-06 Issue:6 Volume:26 Page:1466-1472
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Tripathi Surya Kant^ORCID,Biswal Bijesh K.^ORCID

Funder

Kumoh National Institute of Technology

Ministry of Human Resource Development

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference39 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019

2. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells;Testa;Cancers,2018

3. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants;Guan;Future Med. Chem.,2017

4. Thiazole in the targeted anticancer drug discovery;Ayati;Future Med. Chem.,2019

5. Role of epidermal growth factor receptor in lung cancer and targeted therapies;Liu;Am. J. Cancer Res.,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, In Silico Prediction, and In Vitro Evaluation of Anti-tumor Activities of Novel 4'-Hydroxybiphenyl-4-carboxylic Acid Derivatives as EGFR Allosteric Site Inhibitors;Current Medicinal Chemistry;2024-11

2. Epidermal Growth Factor Receptor (EGFR) Inhibitors Screened from Autodisplayed Fv-Antibody Library;Bioconjugate Chemistry;2024-08-28

3. Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies;Journal of Biomolecular Structure and Dynamics;2023-09-14

4. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders;Expert Opinion on Therapeutic Patents;2023-08-03

5. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance;Japanese Journal of Clinical Oncology;2023-06-03